The mitogen-activated protein (MAP) kinases p38 and extracellular signal-regulated kinase (ERK) are involved in hepatocyte-mediated phenotypic switching in prostate cancer cells

Journal of Biological Chemistry

Volumn 289, Issue 16, 2014, Pages 11153-11161

  Ma, Bo ^a   Wells, Alan ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SIGNALING; CHEMOTHERAPY; DISEASES;

ACTIVITY REGULATION; CANCER THERAPY; EXTRACELLULAR SIGNAL-REGULATED KINASE; METASTATIC SITES; MITOGEN ACTIVATED PROTEIN KINASE; PHENOTYPIC SWITCHING; PROSTATE CANCER CELLS; TUMOR CELLS;

ENZYMES;

CAMPTOTHECIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; STAUROSPORINE; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CELL TYPE; COCULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LIVER CELL; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

E-CADHERIN; EMT; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR); EPITHELIAL TO MESENCHYMAL TRANSITION; MESENCHYMAL TO EPITHELIAL REVERTING TRANSITION; METASTASIS;

CADHERINS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTES; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS;

EID: 84899031389     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.540237     Document Type: Article

References (39)

1. Chaffer, C. L., and Weinberg, R. A. (2011) A perspective on cancer cell metastasis. Science 331, 1559-1564
2. Gunasinghe, N. P., Wells, A., Thompson, E. W., and Hugo, H. J. (2012) Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev. 31, 469-478
3. Wells, A., Chao, Y. L., Grahovac, J., Wu, Q., and Lauffenburger, D. A. (2011) Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front. Biosci. (Landmark Ed) 16, 815-837
4. Kowalski, P. J., Rubin, M. A., and Kleer, C. G. (2003) E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 5, R217-R222
5. Chaffer, C. L., Thompson, E. W., and Williams, E. D. (2007) Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 185, 7-19
6. Saha, B., Chaiwun, B., Imam, S. S., Tsao-Wei, D. D., Groshen, S., Naritoku, W. Y., and Imam, S. A. (2007) Overexpression of E-cadherin protein in metastatic breast cancer cells in bone. Anticancer Res. 27, 3903-3908
7. Chao, Y., Wu, Q., Acquafondata, M., Dhir, R., and Wells, A. (2012) Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron. 5, 19-28
8. Wells, A., Yates, C., and Shepard, C. R. (2008) E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp. Metastasis 25, 621-628
9. Krysan, K., Lee, J. M., Dohadwala, M., Gardner, B. K., Reckamp, K. L., Garon, E., St John, M., Sharma, S., and Dubinett, S. M. (2008) Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J. Thorac. Oncol. 3, 107-110
10. Moustakas, A., and Heldin, C. H. (2012) Induction of epithelial- mesenchymal transition by transforming growth factor α. Semin. Cancer Biol. 22, 446-454
11. Yates, C., Wells, A., and Turner, T. (2005) Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline. Br. J. Cancer 92, 366-375
12. Yates, C. C., Shepard, C. R., Stolz, D. B., and Wells, A. (2007) Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br. J. Cancer 96, 1246-1252
13. Chao, Y., Wu, Q., Shepard, C., and Wells, A. (2012) Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin Exp. Metastasis 29, 39-50
14. Ha, G. H., Park, J. S., and Breuer, E. K. (2013) TACC3 promotes epithelialmesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways. Cancer Lett. 332, 63-73
15. Lim, M., Chuong, C. M., and Roy-Burman, P. (2011) PI3K, Erk signaling in BMP7-induced epithelial-mesenchymal transition (EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional cultures. Horm. Cancer 2, 298-309
16. Horn, G., Gaziel, A., Wreschner, D. H., Smorodinsky, N. I., and Ehrlich, M. (2009) ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1. Exp. Cell Res. 315, 1490-1504
17. Li, Q., and Mattingly, R. R. (2008) Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Ras-transformed breast epithelial cells. Neoplasia 10, 1444-1458
18. Alcorn, J. F., Guala, A. S., van der Velden, J., McElhinney, B., Irvin, C. G., Davis, R. J., and Janssen-Heininger, Y. M. (2008) Jun N-terminal kinase 1 regulates epithelial-to-mesenchymal transition induced by TGF-β1. J. Cell Sci. 121, 1036-1045
19. Zavadil, J., and Böttinger, E. P. (2005) TGF-β and epithelial-to-mesenchymal transitions. Oncogene 24, 5764-5774
20. Zohn, I. E., Li, Y., Skolnik, E. Y., Anderson, K. V., Han, J., and Niswander, L. (2006) p38 and a p38-interacting protein are critical for down-regulation of E-cadherin during mouse gastrulation. Cell 125, 957-969
21. Liu, Y., Martinez, L., Ebine, K., and Abe, M. K. (2008) Role for mitogenactivated protein kinase p38α in lung epithelial branching morphogenesis. Dev. Biol. 314, 224-235
22. Strippoli, R., Benedicto, I., Foronda, M., Perez-Lozano, M. L., Sánchez- Perales, S., López-Cabrera, M., and Del Pozo, M. Á. (2010) p38 maintains E-cadherin expression by modulating TAK1-NF-κB during epithelial-tomesenchymal transition. J. Cell Sci. 123, 4321-4331
23. Han, J., Lee, J. D., Jiang, Y., Li, Z., Feng, L., and Ulevitch, R. J. (1996) Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J. Biol. Chem. 271, 2886-2891
24. Goffin, J. R., and Zbuk, K. (2013) Epidermal growth factor receptor. Pathway, therapies, and pipeline. Clin Ther. 35, 1282-1303
25. Munshi, A., McDonnell, T. J., and Meyn, R. E. (2002) Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother. Pharmacol. 50, 46-52
26. Shankar, S., Chen, X., and Srivastava, R. K. (2005) Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62, 165-186
27. Enslen, H., Brancho, D. M., and Davis, R. J. (2000) Molecular determinants that mediate selective activation of p38MAPkinase isoforms.EMBOJ. 19, 1301-1311
28. Kumar, S., McDonnell, P. C., Gum, R. J., Hand, A. T., Lee, J. C., and Young, P. R. (1997) Novel homologues of CSBP/p38 MAP kinase. Activation, substrate specificity. and sensitivity to inhibition by pyridinyl imidazoles. Biochem. Biophys. Res. Commun. 235, 533-538
29. Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., and Landvatter, S. W. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746
30. Ono, K., and Han, J. (2000) The p38 signal transduction pathway. Activation and function. Cell. Signal. 12, 1-13
31. Cuenda, A., and Rousseau, S. (2007) p38MAPkinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta 1773, 1358-1375
32. Bulavin, D. V., Demidov, O. N., Saito, S., Kauraniemi, P., Phillips, C., Amundson, S. A., Ambrosino, C., Sauter, G., Nebreda, A. R., Anderson, C. W., Kallioniemi, A., Fornace, A. J., Jr., and Appella, E. (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat. Genet. 31, 210-215
33. Yu, W., Imoto, I., Inoue, J., Onda, M., Emi, M., and Inazawa, J. (2007) A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene 26, 1178-1187
34. Elenitoba-Johnson, K. S., Jenson, S. D., Abbott, R. T., Palais, R. A., Bohling, S. D., Lin, Z., Tripp, S., Shami, P. J., Wang, L. Y., Coupland, R. W., Buckstein, R., Perez-Ordonez, B., Perkins, S. L., Dube, I. D., and Lim, M. S. (2003) Involvement of multiple signaling pathways in follicular lymphoma transformation. p38-mitogen-activated protein kinase as a target for therapy. Proc. Natl. Acad. Sci. U.S.A. 100, 7259-7264
35. Esteva, F. J., Sahin, A. A., Smith, T. L., Yang, Y., Pusztai, L., Nahta, R., Buchholz, T. A., Buzdar, A. U., Hortobagyi, G. N., and Bacus, S. S. (2004) Prognostic significance of phosphorylated p38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100, 499-506
36. Demuth, T., Reavie, L. B., Rennert, J. L., Nakada, M., Nakada, S., Hoelzinger, D. B., Beaudry, C. E., Henrichs, A. N., Anderson, E. M., and Berens, M. E. (2007) MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival. Mol. Cancer Ther. 6, 1212-1222
37. Junttila, M. R., Ala-Aho, R., Jokilehto, T., Peltonen, J., Kallajoki, M., Grenman, R., Jaakkola, P., Westermarck, J., and Kähäri, V. M. (2007) p38α and p38δ mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 26, 5267-5279
38. Jackson, R. C. (1989) The problem of the quiescent cancer cell. Adv. Enzyme Regul. 29, 27-46
39. Hong, K. O., Kim, J. H., Hong, J. S., Yoon, H. J., Lee, J. I., Hong, S. P., and Hong S. D. (2009) Inhibition of Akt activity induces the mesenchymal-toepithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells. J. Exp. Clin Cancer Res. 28, 28